The global CRO, PPD, have been announced as the best CRO provider at the World ADC Awards for advancing cancer research.
Weiping Shao discusses biomarkers, immunogenicity and the work he contributes to at Regeneron Pharmaceuticals (NY,USA).
Available to view on demand
We want to assess and mitigate risk from pre-existing antibodies early within clinical development. Will pre-existing antibodies impact our clinical trial?
In this interview Mohsen Rajabi (FDA) discusses the process of FDA approval, why immunogenicity assays are so important and what he believes the future may hold for immunogenicity testing.
This article describes the nature of the immune response to protein therapeutics, their clinical relevance, methodology for measuring it and approaches to interpreting the data.